09/18/23 7:00 AMNasdaq : KYMR clinical trialKymera Therapeutics Receives U.S. FDA Fast Track Designation for KT-333, a First-in-Class, Investigational STAT3 Degrader for the Treatment of Relapsed/Refractory Cutaneous T-Cell Lymphoma and Relapsed/Refractory Peripheral T-Cell LymphomaKT-333 Phase 1 oncology trial ongoing with an update including initial evaluation of its clinical antitumor activity in patients expected in the fourth quarter of 2023 Fast Track designation can potentially accelerate KT-333’s development path for the treatment of R/R Cutaneous T-Cell Lymphoma andRHEA-AIneutral
08/28/23 7:00 AMNasdaq : KYMR conferencesKymera Therapeutics to Participate in Upcoming September Investor ConferencesKymera Therapeutics, Inc. (NASDAQ: KYMR), a clinical-stage biopharmaceutical company advancing targeted protein degradation to deliver novel small molecule protein degrader medicines, today announced that the Company’s management team willRHEA-AIneutral
08/03/23 7:00 AMNasdaq : KYMR earningsKymera Therapeutics Announces Second Quarter 2023 Financial Results and Provides a Business UpdateKT-474/SAR444656 (IRAK4) Phase 2 trials for both hidradenitis suppurativa (HS) and atopic dermatitis (AD) planned to start in 4Q23 by partner Sanofi Phase 1 oncology trials for KT-253 (MDM2), KT-333 (STAT3), and KT-413 (IRAKIMiD) degraders ongoing, with clinical updates planned for later in 2023RHEA-AIneutral
07/27/23 7:00 AMNasdaq : KYMR conferencesearningsKymera Therapeutics to Report Second Quarter 2023 Financial Results on August 3Kymera Therapeutics, Inc. (NASDAQ: KYMR), a clinical-stage biopharmaceutical company advancing targeted protein degradation to deliver novel small molecule protein degrader medicines, will report second quarter 2023 financial results on AugustRHEA-AIneutral
06/22/23 8:30 AMNasdaq : KYMR clinical trialKymera Therapeutics Receives FDA Orphan Drug Designation for KT-253, a Novel, Highly Potent and Selective MDM2 Degrader for the Treatment of Acute Myeloid LeukemiaKymera Therapeutics, Inc. (NASDAQ: KYMR), a clinical-stage biopharmaceutical company advancing targeted protein degradation to deliver novel small molecule protein degrader medicines, today announced that the U.S. Food and Drug AdministrationRHEA-AIneutral
06/14/23 2:30 AMNasdaq : KYMR clinical trialKymera Therapeutics’ STAT3 Degrader KT-333 and IRAKIMiD Degrader KT-413 Demonstrate Desired Target Knockdown and Safety with Continued Dose Escalation in Ongoing Phase I Clinical TrialsData shared today on PK/PD and safety from additional KT-333 and KT-413 patient dose escalation cohorts show target knockdown at or near levels associated with clinical efficacy in preclinical tumor models N o dose limiting toxicities observed in either program KT-333 data will be presented in aRHEA-AIneutral
06/09/23 6:00 PMNasdaq : KYMR clinical trialKymera Therapeutics Announces Updated Clinical Data from the Phase 1 Trials of STAT3 Degrader KT-333 and IRAKIMiD Degrader KT-413Data shared today in abstracts from the International Conference on Malignant Lymphoma (ICML) Both programs continue to demonstrate substantial target knockdown in ongoing clinical trials, with no dose limiting toxicities observed Data on additional KT-333 and KT-413 patient cohorts to be shared inRHEA-AIneutral
06/09/23 3:00 AMNasdaq : KYMR Kymera Therapeutics Presents Data Demonstrating Superior Efficacy of KT-253, a Potent and Selective Heterobifunctional MDM2 Degrader, Compared to Small Molecule Inhibitor in Preclinical Leukemia Models at the European Hematology Association CongressKymera Therapeutics, Inc. (NASDAQ: KYMR), a clinical-stageRHEA-AIneutral
06/01/23 7:00 AMNasdaq : KYMR conferencesKymera Therapeutics to Participate in Upcoming June Investor ConferenceKymera Therapeutics, Inc. (NASDAQ: KYMR), a clinical-stage biopharmaceutical company advancing targeted protein degradation to deliver novel small molecule protein degrader medicines, today announced that the Company’s management team willRHEA-AIneutral
05/22/23 7:00 AMNasdaq : KYMR managementKymera Appoints Jeremy Chadwick, Ph.D., as Chief Operating OfficerKymera Therapeutics, Inc. (NASDAQ: KYMR), a clinical-stage biopharmaceutical company advancing targeted protein degradation (TPD) to deliver novel small molecule protein degrader medicines, today announced the appointment of Jeremy Chadwick,RHEA-AIneutral